Cambridge Investment Research Advisors
BCRX icon

Cambridge Investment Research Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199K Sell
19,853
-3,570
-15% -$32.3K ﹤0.01% 3576
2026
Q1 		$223K Buy
23,423
+3,950
+20% +$30.7K ﹤0.01% 3580
2025
Q4 		$152K Sell
19,473
-2,961
-13% -$21.4K ﹤0.01% 3631
2025
Q3 		$170K Buy
+22,434
New +$187K ﹤0.01% 3525
2022
Q1 		– Sell
-28,463
Closed -$394K – 3167
2021
Q4 		$394K Buy
28,463
+100
+0.4% +$1.32K ﹤0.01% 2298
2021
Q3 		$408K Sell
28,363
-4,902
-15% -$77.3K ﹤0.01% 2203
2021
Q2 		$526K Sell
33,265
-15,044
-31% -$204K ﹤0.01% 2015
2021
Q1 		$491K Buy
48,309
+6,114
+14% +$63K ﹤0.01% 1919
2020
Q4 		$314K Buy
42,195
+6,210
+17% +$32K ﹤0.01% 2095
2020
Q3 		$124K Sell
35,985
-17,420
-33% -$74.7K ﹤0.01% 2363
2020
Q2 		$254K Buy
+53,405
New +$213K ﹤0.01% 2016

Other funds holding BCRX

OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
QFW
QTR Family Wealth Lake Mary, Florida $287M AUM 40.55% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CV
Counterweight Ventures Wilmington, North Carolina $201M AUM 35.56% 1-Year Est. Return

Cambridge Investment Research Advisors's BCRX Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its BioCryst Pharmaceuticals (BCRX) stake by 15% in Q2 2026, selling an estimated $32.3K and leaving 19,853 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #3576.

Cambridge Investment Research Advisors first reported a position in BCRX in Q2 2020 and has held it in 11 quarters since. The position peaked at $526K in Q2 2021. 52 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Cambridge Investment Research Advisors held 19,853 shares of BioCryst Pharmaceuticals worth $199K as of Q2 2026.
  • Cambridge Investment Research Advisors sold 3,570 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $32.3K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3576 holding.
  • Cambridge Investment Research Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2020 and has held it in 11 quarters since.
  • Cambridge Investment Research Advisors's BioCryst Pharmaceuticals position peaked at $526K in Q2 2021.
  • 52 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.